Business

Mass. Movers

Biogen Idec slips as MS drug’s sales slow

George A. Scangos is chief executive of Biogen Idec.

Jessica Rinaldi For The Globe

George A. Scangos is chief executive of Biogen Idec.

Advertisement

Biogen Idec Inc. fell after demand for its multiple sclerosis drug Tecfidera showed signs of slowing. Prescriptions fell 6.7 percent in the week ended Aug. 2 to 3,377 from the previous week, IMS Health Inc. said. Tecfidera, said Gabelli & Co.’s Kevin Kedra, is “the newest oral MS product . . . It’s gotten off to a very strong launch, so any signs of them maybe slowing down would be a positive for competitors” like Teva Pharmaceutical, Bloomberg reported. Biogen Idec said it doesn’t comment on sales reports.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.